Allogene Taps Adaptimmune’s Rafael Amado as Chief Medical Officer

Rafael Amado has been appointed executive vice president of research and development and chief medical officer of Allogene Therapeutics (NASDAQ: [[ticker:ALLO]]). He joins the South San Francisco cancer drug developer from Adaptimmune, where he was president of research and development. His experience also includes positions at GlaxoSmithKline (NYSE: [[ticker:GSK]]) and Amgen (NASDAQ: [[ticker:AMGN]]). Amado is expected to start his new position in early September. Allogene is developing “off-the-shelf” cancer cell therapies made from immune cells that come from healthy donors.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan